

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: NUDLER2A

In re Application of:)	Art Unit:
)	
Evgeny NUDLER et al)	Examiner:
)	
Appln. No.: Not yet assigned)	Confirmation No.
)	
Filed: September 17, 2003)	Washington, D.C.
)	
For: CONTROL OF NITRIC OXIDE)	September 17, 2003
BIOACTIVITY ...)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application; and before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office,

In re Appln. No.

either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except documents AA-AG are U.S. patent(s) and/or published applications. As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration - Pre O.G. Notice of July 11, 2003).


3.No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4.In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Anne M. Kornbau
Reg. No. 25,884

AMK:gsk

624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

G:\BN\N\nyum\Nudler 2A\PTO\IDS.doc

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not yet assigned
				Filing Date	September 17, 2003
				First Named Inventor	Evgeny NUDLER
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	NUDLER2A

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

Complete if Known

Application Number	Not yet assigned
Filing Date	September 17, 2003
First Named Inventor	Evgeny NUDLER
Group Art Unit	
Examiner Name	
Attorney Docket Number	NUDLER2A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AH	"Regulation of Basal Myocardial Function by NO," <u>Cardiovascular Research</u> , Georg KOJDA et al, 1999	
	AI	"Potential Therapeutic Uses for S-Nitrosothiols," <u>Clinical Science</u> , G. RICHARDSON et al, 2002	
	AJ	"S-Nitrosothiols: A Class of Nitric Oxide-Donor Drugs," <u>Clinical Science</u> , Haitham AL-SA'DONI et al, 2000	
	AK	"Selective Pharmacological Inhibition of Distinct Nitric Oxide Synthase Isoforms," <u>Biochemical Pharmacology</u> , Vol. 51, Garry J. SOUTHAN et al, 1996	
	AL	"Effects of Nitric Oxide Synthase Blockers on Renal Function," <u>Nephrol Dial Transplant</u> , Francis B. GABBAL, 2001.	
	AM	"Is Nitric Oxide Overproduction the Target of Choice for the Management of Septic Shock?," <u>Pharmacology & Therapeutics</u> , Vol. 91, Francois FEIHL et al, 2001	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.